Statements (68)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology company
|
| gptkbp:acquisition |
MediGene_AG_(formerly_known_as_Medigene_AG)
|
| gptkbp:businessModel |
research and development
strategic alliances |
| gptkbp:CEO |
Kai_Pinkernell
|
| gptkbp:clinicalTrials |
gptkb:Germany
regulatory compliance Phase 2 multiple phases ongoing studies specific cancer types efficacy and safety solid tumors real-world evidence cellular therapies positive results patients with cancer immune-oncology published data adaptive trials Phase 1/2 T cell therapies |
| gptkbp:collaborations |
gptkb:University_of_Munich
|
| gptkbp:community_service |
survival rates
|
| gptkbp:communityPartnerships |
collaborative projects
biopharmaceutical companies |
| gptkbp:employeeCount |
approximately 100
|
| gptkbp:focus |
immunotherapy
|
| gptkbp:founded |
1997
|
| gptkbp:hasPrograms |
experts in immunology
|
| gptkbp:headquarters |
gptkb:Planegg,_Germany
|
| gptkbp:historicalResearch |
cancer immunotherapy
international research networks |
| https://www.w3.org/2000/01/rdf-schema#label |
Medigene AG
|
| gptkbp:impact |
personalized medicine
|
| gptkbp:investmentFocus |
annual reports
financial performance venture capital firms biopharmaceutical research |
| gptkbp:leads |
MDG1011
|
| gptkbp:manufacturer |
healthcare
|
| gptkbp:market |
approximately €200 million
|
| gptkbp:marketSegment |
global expansion
|
| gptkbp:partnerships |
gptkb:Astellas_Pharma
academic institutions |
| gptkbp:patentCitation |
T cell receptor technology
|
| gptkbp:productLine |
various therapies
|
| gptkbp:products |
therapeutic vaccines
T cell receptor therapies |
| gptkbp:regulatoryCompliance |
gptkb:European_Medicines_Agency
clinical trial applications |
| gptkbp:research |
public and private sources
|
| gptkbp:research_areas |
oncology
novel treatments |
| gptkbp:researchAreas |
cancer treatment
|
| gptkbp:researchFocus |
immune response
|
| gptkbp:researchInterest |
gptkb:Max_Planck_Institute
peer-reviewed journals pharmaceutical companies government funding |
| gptkbp:scientificName |
leading researchers
|
| gptkbp:stockSymbol |
MDG1
|
| gptkbp:subsidiary |
gptkb:Medigene_Immunotherapies_GmbH
|
| gptkbp:technology |
T cell receptor engineering
DC-based_immunotherapy |
| gptkbp:tradedOn |
gptkb:Frankfurt_Stock_Exchange
|
| gptkbp:tributaryOf |
TCR-based_therapies
|
| gptkbp:website |
www.medigene.com
|